Ordessia Charran, MD
Critical Care Medicine · Kingman, AZNPI 1114345345
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.3% of the total across 32 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by GSK at 26.2% of the total. Reporting peaked in 2021 at $525 and has fallen 81.0% since, to $100 in 2025.
Across 32 payments — averaging $36.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$303
- AstraZeneca$270
- Philips North America LLC$169
- Mylan Specialty L.p.$116
- Sanofi-aventis U.S. LLC$100
- Actelion Pharmaceuticals US, Inc.$64
- plus $133 from 7 others
What the payments were for
- Food & beverage$1,05691%
- Education$1009%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 7 | $303 |
| AstraZeneca | 3 | $270 |
| Philips North America LLC | 3 | $169 |
| Mylan Specialty L.p. | 9 | $116 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Actelion Pharmaceuticals US, Inc. | 1 | $64 |
| Boehringer Ingelheim | 2 | $33 |
| Advanced Respiratory, Inc | 1 | $22 |
| ZOLL Respicardia, Inc. | 1 | $19 |
| Harmony Biosciences LLC | 1 | $17 |
| United Therapeutics Corporation | 1 | $16 |
| La Jolla Pharmaceutical Company | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$123
- TRELEGY ELLIPTA$122
- TEZSPIRE$122
- FASENRA$119
How this compares
$1,156 in reported general payments places this provider in the 70th percentile of 175 critical care medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 189 | $144,236 |
| TezspireTezepelumab-Ekko | 22 | $96,375 |
| Spiriva RespimatTiotropium Bromide | 65 | $55,004 |
| Spiriva HandihalerTiotropium Bromide | 30 | $27,149 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 39 | $20,585 |
| SymbicortBudesonide/Formoterol Fumarate | 50 | $19,466 |
| Advair HfaFluticasone Propion/Salmeterol | 45 | $18,354 |
| Incruse ElliptaUmeclidinium Bromide | 37 | $15,618 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $11,262 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 19 | $10,693 |
| DuleraMometasone/Formoterol | 30 | $9,659 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 254 | $7,057 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $6,937 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 22 | $5,319 |
| Varenicline Tartrate | 20 | $5,035 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta, Anoro Ellipta | $303 | $178,054262 claims |
| AstraZenecaTezspire, Symbicort | $270 | $115,84172 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $33 | $86,282123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 175 critical care medicine providers in Arizona.
Other critical care medicine in Kingman
- Robert MathenyKingman$10K
- Naomi HabibPhoenix$298K
- Heather PrzybylPhoenix$126K
- Douglas MapelPrescott$125K
- Akshay MuralidharScottsdale$44K
- Syed ShahryarPhoenix$20K
- Rodrigo Cartin-CebaScottsdale$18K
- Reena BansalScottsdale$10K
- Lina AnthonyMesa$6K
- Blythe DemelloTucson$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.